Volume 30, Number 2—February 2024
Dispatch
Critically Ill Patients with Visceral Nocardia Infection, France and Belgium, 2004–2023
Table 1
Baseline characteristics | Nocardiosis cases, n = 50 |
---|---|
Age, y, median (IQR) |
59 (47–67) |
Sex | |
M | 39 (78) |
F |
11 (22) |
Charlson score, median (IQR) | 4 (3–7) |
Cardiovascular risk factors, median (IQR) |
2 (1–3) |
Immunosuppression | 46 (92) |
Corticosteroids at admission | 34 (68) |
5–10 mg/d | 5 (10) |
>10 mg/d | 29 (58) |
Tacrolimus treatment | 16 (32) |
Mycophenolate mofetil treatment | 12 (24) |
Other conventional immunosuppressive drugs† |
5 (10) |
Organ transplantation | 18 (36) |
Kidney | 12 (24) |
Heart | 4 (8) |
Liver | 1 (2) |
Lung |
1 (2) |
Systemic autoimmune disease‡ |
12 (24) |
Hematologic malignancies | 10 20) |
Aggressive B cell lymphoma | 6 (12) |
Acute lymphoid leukemia | 3 (6) |
Acute myeloid leukemia |
1 (2) |
No. lymphocytes/mm3, median (IQR) | 552 (287–1,210) |
Gamma globulin, g/L, median (IQR) | 6 (4–10) |
Trimethoprim/sulfamethoxazole prophylaxis | 12 (24) |
*Values are no. (%) except as indicated. IQR, interquartile range. †Azathioprine, n = 4 (8%); methotrexate, n = 1 (2%). ‡Connective tissue disease, n = 2; glomerulonephritis, n = 1; periarteritis nodos, n = 1; bullous pemphigoid, n = 1; Evans syndrome, n = 1; IgA vasculitis, n = 1; type 1 diabetes, n = 1; myasthenia gravis, n = 1; sarcoidosis, n = 1; chronic inflammatory demyelinating polyradiculoneuropathy, n = 1; inflammatory bowel disease, n = 1.
Page created: December 21, 2023
Page updated: January 24, 2024
Page reviewed: January 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.